MarketWatch
The Wegovy pill is still dominating the GLP-1 pill market
It has remained a top choice among Americans trying to lose weight even after the launch of Foundayo, Eli Lilly’s GLP-1 pill.
View original source — MarketWatch ↗
Related stories
Financial Times
HealthJun 8, 2026 · 1 min
AstraZeneca advances weight-loss pill to take aim at obesity leaders
Financial Times
CNBC
WorldJun 8, 2026 · 1 min
Novo and Lilly are competing to win the GLP-1 pill market as they prepare for Medicare coverage
CNBC
MarketWatch
WorldJun 6, 2026 · 1 min
Tired of nausea or taking a GLP-1 pill every day? These experimental drugs could be better than Zepbound and Wegovy.
MarketWatch
Bloomberg
WorldJun 17, 2026 · 1 min
GLP-1 Craze Fuels Protein-Powder Maker Glanbia’s Share Rally
Bloomberg